Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Nasdaq

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart at ASCO 2025, Advancing Tumor-Activated Immuno-Oncology Pipeline

Xilio Therapeutics, a clinical-stage biotechnology company, announced progress on its pipeline and first-quarter financial results, highlighting initial Phase 2 data for vilastobart, a tumor-activated ...
Managed Healthcare Executive

Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...
Seeking Alpha

Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout

Xenon Pharmaceuticals is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near ...
FierceBiotech

Pfizer's parade of pipeline cuts: Seagen, BioNTech and MASH programs among 11 axed

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...
Upstream

Earlier start-up deadline for pipeline’s phase two

According to Transneft vice president Mikhail Barkov, the start-up of oil pumping from the town of Skovorodino to Kozmino is now expected between October and November. Earlier this year, Transneft ...
Insider Monkey

Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating ...